Emerging Drug Therapies: Transforming the HR+/HER2- Breast Cancer...

heeft een bestand toegevoegd Health

2024-10-09 08:13:39 -

Emerging Drug Therapies: Transforming the HR+/HER2- Breast Cancer Treatment Paradigm

Introduction HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, accounting for approximately 70% of cases. This subtype, characterized by hormone receptor positivity and the absence of HER2 overexpression, has historically been treated with hormonal therapies and chemotherapy. However, emerging drug therapies are revolutionizing the treatment landscape, offering new...

0 Reacties 0 aandelen 161 Views 0 voorbeeld